Literature DB >> 16436757

Evaluation of high- versus standard-dose rifampin in Indonesian patients with pulmonary tuberculosis.

Rovina Ruslami, Hanneke Nijland, Rob Aarnoutse, Bachti Alisjahbana, Arto Yuwono Soeroto, Suzanne Ewalds, Reinout van Crevel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16436757      PMCID： PMC1366934          DOI： 10.1128/AAC.50.2.822-823.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  6 in total

1.  Two three-month treatment regimens for pulmonary tuberculosis.

Authors:  B Kreis; S Pretet; J Birenbaum; P Guibout; J J Hazeman; E Orin; S Perdrizet; J Weil
Journal:  Bull Int Union Tuberc       Date:  1976

2.  What is the 'right' dose of rifampin?

Authors:  Charles Peloquin
Journal:  Int J Tuberc Lung Dis       Date:  2003-01       Impact factor: 2.373

Review 3.  Therapeutic drug monitoring in the treatment of tuberculosis.

Authors:  Charles A Peloquin
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 4.  Role of individual drugs in the chemotherapy of tuberculosis.

Authors:  D A Mitchison
Journal:  Int J Tuberc Lung Dis       Date:  2000-09       Impact factor: 2.373

5.  Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis.

Authors:  Ramesh Jayaram; Sheshagiri Gaonkar; Parvinder Kaur; B L Suresh; B N Mahesh; R Jayashree; Vrinda Nandi; Sowmya Bharat; R K Shandil; E Kantharaj; V Balasubramanian
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

6.  Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia.

Authors:  R van Crevel; B Alisjahbana; W C M de Lange; F Borst; H Danusantoso; J W M van der Meer; D Burger; R H H Nelwan
Journal:  Int J Tuberc Lung Dis       Date:  2002-06       Impact factor: 2.373
  6 in total
  13 in total

1.  Plasma drug activity assay for treatment optimization in tuberculosis patients.

Authors:  Scott K Heysell; Charles Mtabho; Stellah Mpagama; Solomon Mwaigwisya; Suporn Pholwat; Norah Ndusilo; Jean Gratz; Rob E Aarnoutse; Gibson S Kibiki; Eric R Houpt
Journal:  Antimicrob Agents Chemother       Date:  2011-10-03       Impact factor: 5.191

Review 2.  Tuberculosis pharmacotherapy: strategies to optimize patient care.

Authors:  Carole D Mitnick; Bryan McGee; Charles A Peloquin
Journal:  Expert Opin Pharmacother       Date:  2009-02       Impact factor: 3.889

3.  Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial.

Authors:  Gustavo E Velásquez; Meredith B Brooks; Julia M Coit; Henry Pertinez; Dante Vargas Vásquez; Epifanio Sánchez Garavito; Roger I Calderón; Judith Jiménez; Karen Tintaya; Charles A Peloquin; Elna Osso; Dylan B Tierney; Kwonjune J Seung; Leonid Lecca; Geraint R Davies; Carole D Mitnick
Journal:  Am J Respir Crit Care Med       Date:  2018-09-01       Impact factor: 21.405

Review 4.  Therapeutic drug monitoring in the treatment of tuberculosis: an update.

Authors:  Abdullah Alsultan; Charles A Peloquin
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

5.  Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines.

Authors:  Helen McIlleron; Roxana Rustomjee; Mahnaz Vahedi; Thuli Mthiyane; Paolo Denti; Catherine Connolly; Wasima Rida; Alexander Pym; Peter J Smith; Philip C Onyebujoh
Journal:  Antimicrob Agents Chemother       Date:  2012-03-12       Impact factor: 5.191

6.  Influence of daily dosage and frequency of administration of rifampicin-levofloxacin therapy on tolerance and effectiveness in 154 patients treated for prosthetic joint infections.

Authors:  S Nguyen; O Robineau; M Titecat; N Blondiaux; M Valette; C Loiez; E Beltrand; H Migaud; E Senneville
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-05-19       Impact factor: 3.267

7.  A semimechanistic pharmacokinetic-enzyme turnover model for rifampin autoinduction in adult tuberculosis patients.

Authors:  Wynand Smythe; Akash Khandelwal; Corinne Merle; Roxana Rustomjee; Martin Gninafon; Mame Bocar Lo; Oumou Bah Sow; Piero L Olliaro; Christian Lienhardt; John Horton; Peter Smith; Helen McIlleron; Ulrika S H Simonsson
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

8.  Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.

Authors:  Rovina Ruslami; Hanneke M J Nijland; Bachti Alisjahbana; Ida Parwati; Reinout van Crevel; Rob E Aarnoutse
Journal:  Antimicrob Agents Chemother       Date:  2007-04-23       Impact factor: 5.191

9.  Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes.

Authors:  Rovina Ruslami; Hanneke M J Nijland; I Gusti N Adhiarta; Sri H K S Kariadi; Bachti Alisjahbana; Rob E Aarnoutse; Reinout van Crevel
Journal:  Antimicrob Agents Chemother       Date:  2009-12-28       Impact factor: 5.191

10.  Intensified treatment with high dose rifampicin and levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM-IT): protocol for a randomized controlled trial.

Authors:  Dorothee Heemskerk; Jeremy Day; Tran Thi Hong Chau; Nguyen Huy Dung; Nguyen Thi Bich Yen; Nguyen Duc Bang; Laura Merson; Piero Olliaro; Thomas Pouplin; Maxine Caws; Marcel Wolbers; Jeremy Farrar
Journal:  Trials       Date:  2011-02-02       Impact factor: 2.279
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.